

FD-1390 (Modified)  
(11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S LOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

SHIM1110

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/762641

INTERNATIONAL APPLICATION NO.

PCT/JP99/04333

INTERNATIONAL FILING DATE

10 August 1999 (10/08/99)

PRIORITY DATE CLAIMED

11 August 1998 (11/08/98)

TITLE OF INVENTION

**RNA VIRUS VECTOR WITH CONTACT INFILTRATION CAPABILITY**

APPLICANT(S) FOR DO/EO/US

**Makoto Asakawa and Mamoru Hasegawa**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

**Exhibit A - 3 pages****Postcard****Check No. 467735 in the amount of \$ 485.00****Express Mail Label No.: EL617036867US**

APPLICATION NO. (IF KNOWN, SEE 37 CFR) <div style="font-size: 24pt; font-weight: bold;">09/762641</div>		INTERNATIONAL APPLICATION NO. <div style="font-weight: bold;">PCT/JP99/04333</div>		ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold;">SHIM1100</div>	
--	--	---	--	--	--

21. The following fees are submitted: <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5)) :</b>				CALCULATIONS    PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$970.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00				<div style="border: 1px solid black; padding: 2px; width: 100%;"> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>  <div style="text-align: right; font-weight: bold;">\$840.00</div> </div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<div style="border: 1px solid black; padding: 2px; width: 100%;"> <b>\$130.00</b> </div>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$970.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				\$485.00	
SUBTOTAL =				\$485.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$485.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$485.00	
				Amount to be: refunded \$	
				charged \$	

☒ A check in the amount of **\$485.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-1355** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Lisa A. Haile, Ph.D.  
 GRAY CARY WARE & FREIDENRICH  
 1465 Executive Drive, Suite 1600  
 San Diego, California 92121-2189

Lisa A. Haile

SIGNATURE

Lisa A. Haile, Ph.D.

NAME

**38,347**

REGISTRATION NUMBER

**08 February 2001**

DATE

PATENT  
Attorney Docket No.: SHIM1100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Asakawa and Hasegawa      Art Unit: Not yet assigned  
Serial No.: Not yet assigned      Examiner: Not yet assigned  
Filed: February 8, 2001  
Based on: PCT/JP99/04333  
Internat'l. August 10, 1999      Priority: August 11, 1998  
Filing Date:      Date:  
Title: RNA VIRUS VECTOR WITH CONTACT INFILTRATION CAPABILITY

BOX PCT  
Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Sir:


In connection with the above-identified patent application, entry of the amendments and consideration of the following remarks are respectfully requested.

**AMENDMENTS**

Please amend the claims as follows:

6. (Amended) The RNA molecule [according to any one of claims 1 to 5] of claim 1, wherein said RNA molecule comprises a foreign gene.

7. (Amended) A cell comprising [the RNA according to any one of claims 1 to 6] the RNA molecule of claim 1, wherein the cell is capable of allowing said RNA to replicate and transmitting said RNA to another cell through contact infiltration.

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL"</b>
"EXPRESS MAIL" MAILING LABEL NO. <u>EL617036867US</u>
DATE OF DEPOSIT: <u>08 February 2001</u>
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, Box PCT
Mikhail Bayley
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

In re Application of  
Asakawa and Hasegawa  
Application No.: Not yet assigned  
Filed: February 8, 2001

PATENT  
Attorney Docket No.: SHIM1100

Based on International Appl. No. PCT/JP99/04333  
International Filing Date: August 10, 1999  
Page 2

7. (Amended) A cell comprising [the RNA according to any one of claims 1 to 6] the RNA molecule of claim 1, wherein the cell is capable of allowing said RNA to replicate and transmitting said RNA to another cell through contact infiltration.

8. (Amended) A DNA molecule comprising a template DNA for transcribing the RNA [according to any one of claims 1 to 6] molecule of claim 1 *in vitro* or in cells.

9. (Amended) A complex capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination, wherein said complex comprises the RNA molecule of [ any one of claims 1 to 6] claim 1 and a virus structure without nucleic acid.

10. (Amended) A kit comprising

a) the RNA [according to any of claims 1 to 6] molecule of claim 1, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and

b) a group of enzymes required for replication of said RNA or said cRNA, or a unit that is capable of biosynthesizing said enzymes.

11. (Amended) The kit according to claim 10, wherein

a) the RNA molecule of claim 1 is derived from Sendai virus and comprises no or inactivated gene encoding M protein [is the RNA according to claim 5 or 6, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA], and

b) the group of enzymes comprises [is] all of the proteins, NP, P/C, and L of Sendai virus[, or a unit that is capable of biosynthesizing said proteins].

In re Application of

Asakawa and Hasegawa

Application No.: Not yet assigned

Filed: February 8, 2001

Based on International Appl. No. PCT/JP99/04333

International Filing Date: August 10, 1999

Page 3

PATENT

Attorney Docket No.: SHIM1100

12. (Amended) A method for producing a complex capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination [the complex according to claim 9], [wherein said] the method [comprises] comprising introducing into a host

- a) the RNA [of any one of claims 1 to 6] molecule of claim 1, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and
- b) a group of enzymes required for replication of said RNA or said cRNA, or a unit that is capable of biosynthesizing said enzymes.

13. (Amended) The method according to claim 12, wherein

- a) the RNA molecule of claim 1 is derived from Sendai virus and comprises no or inactivated gene encoding M protein [is the RNA of claim 5 or 6, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA], and
- b) [is] the group of enzymes comprises all of the proteins, NP, P/C, and L of Sendai virus[, or a unit that is capable of biosynthesizing said proteins].

Please add the following new claims:

--15. The kit according to claim 10, wherein

- a) the RNA molecule comprises a foreign gene, and
- b) the group of enzymes comprises all of the proteins, NP, P/C, and L of Sendai virus, or a unit that is capable of biosynthesizing said proteins.

In re Application of  
Asakawa and Hasegawa  
Application No.: Not yet assigned  
Filed: February 8, 2001

PATENT  
Attorney Docket No.: SHIM1100

Based on International Appl. No. PCT/JP99/04333  
International Filing Date: August 10, 1999  
Page 4

16. The method according to claim 12, wherein
- a) the RNA molecule comprises a foreign gene, and
  - b) the group of enzymes comprises all of the proteins, NP, P/C, and L of Sendai virus, or a unit that is capable of biosynthesizing said proteins.--

### REMARKS

Upon entry of the present amendment, claims 1 to 16 will be pending. For the Examiner's convenience, a copy of the claims as they will stand upon entry of the amendment is attached as Exhibit A.

The claims have been amended to address formalities. The claims have been generally amended to remove multiple dependencies. These amendments do not add new matter.

In addition, claims 11 and 13, each of which depended from claims 5 and 6, have been amended to recite the language of claim 5. As such, the amendments to claims 11 and 13 are supported by original claims 11 and 13, respectively, and original claim 5, and, therefore, do not add new matter.

Further to the amendment to claims 11 and 13 as discussed above, new claims 15 and 16 have been added. New claims 15 and 16 are directed to the subject matter of previously pending claims 11 and 13, respectively, with respect to the subject matter of claim 6. As such, new claims 15 and 16 are supported by original claims 11 and 13, respectively, and original claim 6, and, therefore, do not add new matter.

In re Application of

Asakawa and Hasegawa

Application No.: Not yet assigned

Filed: February 8, 2001

Based on International Appl. No. PCT/JP99/04333

International Filing Date: August 10, 1999

Page 5

PATENT

Attorney Docket No.: SHIM1100

In summary, the amendments and new claims address formalities and are supported by the claims as originally filed, and, therefore, do not add new matter. Accordingly, entry of the amendments and new claims is respectfully requested.

It is submitted that the claims are in condition for allowance, and a notice to that effect respectfully is requested. The Examiner is invited to contact Applicants' undersigned representative if there are any questions relating to this application.

Please charge any additional fees, or make any credits, to Deposit Account No. 50-1355.

Respectfully submitted,

Date:

2/8/01

Lisa A. Haile

Lisa A. Haile, Ph.D.

Reg. No. 38,347

Attorney for Applicant

Telephone No.: (858) 677-1456

Facsimile No.: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP

4365 Executive Drive, Suite 1600

San Diego, California 92121-2189

Enclosure: Exhibit A

0976244 07004  
FO02/01 77929/50

DESCRIPTION PCT Rec'd 11 JUN 2001

## RNA VIRUS VECTOR WITH CONTACT INFILTRATION CAPABILITY

Technical Field

[0001] The present invention relates to a virus vector that can be used for gene therapy, and more specifically, to an inactivated negative strand RNA ((-)RNA) viral vector.

Background Art

[0002] In gene therapy for humans and animals, effectiveness and safety are very important. Particularly, in therapy using a "virus vector" which is obtained by viral gene recombination, treatment must be carried out with extreme care, when it is hard to discriminate the possibilities of nonspecific chromosomal integration, and leakage of recombinant or pathogenic viruses to nature, uncontrolled expression of an introduced gene even if the treatment is effective.

[0003] Virus vectors are mainly used for introducing a gene of interest into target cells by utilizing viral infectivity. Recombinant virus vectors, which have been genetically engineered to carry a gene insert(s), contain viral envelope proteins on the surface. Since the envelope proteins retain viral infectivity, it is possible to introduce its endogeneous recombinant gene inserts into cells. These vectors can be utilized for not only gene therapy but also production of cells expressing a gene of interest and creation of transgenic animals.

[0004] Virus vectors are classified into three: retrovirus vectors, DNA virus vectors, and RNA virus vectors. Among them, RNA virus vectors which are not integrated into chromosomes, are advantageous in terms of safety. According to this technical background, virus vectors derived from non-segmented (-)RNA virus such as Sendai virus have already been provided (D. Yu et al., Genes to Cells, 2:457-466, 1997; M. Hasan et al., J. Gen. Virol. 78:2813-2820, 1997). The present inventors have developed a (-)RNA virus vector that has infectivity and autonomous RNA replication ability without disseminative capability (WO 97/16538).



Disclosure of the Invention

[0005] An objective of the present invention is to provide an RNA virus vector that can be used for gene therapy.

[0006] Using nucleic acid of Sendai virus, a representative of (-)RNA viruses, which is supposed to be the most useful vector for industrial applications in terms of safety and convenience, the present inventors succeeded in obtaining various defective mutants, which was experimentally reconstituted using known methods. As a result, the inventors found that the complexes reconstituted by the mutants carrying a defect in M gene were capable of forming plaques, which were smaller than those formed by wild type viruses, but incapable of propagating in embryonated chicken eggs. Thus, the inventors confirmed that the mutants are capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination. Furthermore, the plaques formed by a defective mutant carrying defect in the M gene were stained with anti-Sendai virus antibody, but not with anti-M monoclonal antibody. From this result the inventors confirmed that plaques formed by the M mutants are lacking complete M protein, thereby accomplishing the present invention.

[0007] Thus, the present invention provides RNA comprising genes involved in contact infiltration and autonomous RNA replication, but no or inactivated genes involved in dissemination.

[0008] The present invention also provides a cell comprising the above-described RNA, which is capable of allowing the RNA to replicate therein and transmitting said RNA to another cell through contact infiltration.

[0009] Furthermore, the present invention provides a complex capable of cell infection, contact infiltration, and autonomous RNA replication but incapable of dissemination, a method for producing the complex, and a kit and host for producing the complex.

[0010] Moreover, the present invention provides a DNA comprising a template DNA for transcribing the above-described RNA *in vitro* or in a cell.

[0011] Herein, "cell infectivity" of a virus vector means "an ability of a viral vector capable of cell adhesion and membrane fusion to introduce its endogeneous nucleic acids into cells." "Disseminative capability" means "an ability of a nucleic acid introduced into a cell

09762641.072001

artificially or by infection to form infective particles or comparable complexes following replication of said nucleic acid in the cell, and then be transmitted into another cell."

"Contact infiltration capability" means "an ability of a cell carrying a viral vector gene to transfer the gene to another cell through contact."

[0012] A viral vector capable of contact infiltration but incapable of dissemination can overcome a critical demerit of existing virus vectors, which are incapable of dissemination and contact infiltration. In other words, when cells are infected with a virus vector to express a gene insert in the virus vector, the existing virus vectors are only able to express a protein in cells directly infected. This is not a problem when cell culture systems are used, in which the cells grow in a layer and can be directly infected with viral vectors. However, when *in vivo* cells that exist three-dimensionally in multi-layers are infected with viral vectors, the region and the number of cells directly infected by the existing vectors are limited. For example, it is extremely difficult to directly infect all tumor-forming cells at a tumor site with the viral vectors.

[0013] By contrast, even if virus vectors capable of contact infiltration of the present invention is used to infect tumor cells at a tumor site and only a part of the cells are directly infected, noninfected cells adjacent to the infected cells can be infected with the vectors through contact infiltration, resulting in infecting all the tumor cells. Since the vector is not disseminative, there is no possibility that the vector infects other cells in the body through blood stream.

[0014] Thus, the virus vector of the present invention has such novel features that it infects all the cells in a restricted region or a particular organ and does not infect the other part of the body.

[0015] Furthermore, cells carrying the virus vector of the present invention capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination, can be utilized for cell transplantation. Since a cell carrying a virus vector capable of autonomous replication and contact infiltration can transfer the vector to another cell, it is possible to transplant the cell carrying the vector at the minimal dose to a diseased site, thereby treating there.

09762641.072001  
100220-1499260

[0016] It has been reported that the formation of infective particles of Measles virus having a defect in the M gene is inhibited, and cell fusion is promoted (T. Cathomen et al., EMBO J., 17:3899-3908, 1998). However, the possibility to utilize the virus as a vector has not been suggested.

[0017] A source of a (-)RNA virus of the present invention includes Sendai virus, Newcastle disease virus, Mumps virus, Measles virus, Respiratory syncytial virus, rinderpest virus, and distemper virus of the Paramyxoviridae; influenza virus of the Orthomyxoviridae, and Vesicular S, and Rabies virus of the rhabdoviridae. Incomplete viruses such as DI particle (J. Virol. 68:8413-8417, 1994) and synthetic oligonucleotides can also be used.

[0018] A recombinant (-)RNA virus derived from any viruses described above can also be used as a vector source. For example, the recombinant (-)RNA viruses may be those with the gene for antigenicity inactivated or those with some genes altered to improve efficiency of RNA transcription or replication.

[0019] An RNA of the present invention can be obtained by transcribing an altered cDNA derived from any viruses or recombinant viruses described above *in vitro* or in cells. In the obtained RNA, at least one gene involved in disseminative capability of the original virus must be deleted or inactivated, but gene involved in autonomous replication and contact infiltration should not be deleted or inactivated. In addition, an RNA molecule with artificial sequences, which are prepared by transcribing *in vitro* or in cells a DNA obtained by inserting genes for autonomous replication into a cDNA containing the structure of both ends of a virus genome such as DI molecules can also be used.

[0020] In Sendai virus, "genes involved in autonomous replication" are either of NP, P/C, or L genes, and "genes involved in transmission" are either of M, F, or HN genes. When only the M gene is deleted or inactivated, "disseminative capability" will be lost, but "contact infiltration ability" will remain because virion or virus-like particles capable of releasing the complex containing genomic RNA extracellularly are not formed. Therefore, for example, an RNA of Sendai virus Z strain deficient in only the M gene and a ribonucleoprotein (RNP) comprising said RNA are suitably used in the present invention. The genes are not necessary to be the same as the original viral sequences. They can be mutated or substituted by the

0976641-072001

corresponding gene of other viruses as long as the resulting gene has transcription and replication activities comparable to or higher than those of the wild type.

[0021] An RNA of the present invention may have a foreign gene inserted to an appropriate site. To express a desired protein, a foreign gene encoding the protein is inserted. In the case of Sendai virus RNA (GenBank accession No. M30202), a sequence with a multiple of six bases between the R1 and R2 sequences (J. Virol., Vol. 67, No. 8, 1993, 4822-4830). The consensus sequences of R1 and R2 are 5'-AGGGWBAAWGD-3' and 5'-DTAAGAAAAA-3', respectively. The expression level of the inserted foreign gene can be regulated by the inserted position or the RNA nucleotide sequences flanking the inserted gene. For example, it is known about Sendai virus RNA that the expression level of the inserted gene is higher as the insert position is nearer to the NP gene.

[0022] A complex of the present invention comprises a virus structure without the above-described RNA and nucleic acid. "A virus structure without nucleic acid" is, for example, a virus from which only RNA is removed and complements infectivity and autonomous replication ability of the RNA of the present invention, not complement ability to form particles that release the complex extracellularly and move freely, in other words, not complement the disseminative capability. In Sendai virus, a complex of the RNA in which only the M gene is deleted and the virus structure from which the RNA and M protein are removed (RNP), has infectivity and autonomous replication ability, but not disseminative capability. The complex can contain any other components as long as they do not exhibit disseminative capability. For example, molecules that binds to a specific cell, such as adhesion molecules, ligands, or receptors, can be included on the envelope surface.

[0023] Moreover, the present invention relates to a kit comprising a) the above-described RNA of the present invention, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and b) a group of enzymes required for replication of said RNA or said cRNA, or a unit that is capable of biosynthesizing said enzymes. The complex of the present invention, which is capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination, can be produced by introducing units of a) and b) into an appropriate host. Producing the complex of the present invention means reconstituting an RNP having autonomous replication ability. When RNA

09762541.072001

derived from Sendai virus is used for a), b) is preferably all of NP, P/C, and L proteins derived from Sendai virus or a unit capable of biosynthesizing said proteins.

[0024] A host is not limited as long as it allows virus RNA used to be expressed therein. When RNA derived from Sendai virus is used, any cells susceptible to the infection with Sendai virus can be used, including cultured mammalian cells, cultured avian cells, and embryonated chicken eggs. Examples of cultured cells are LLCMK2, MDCK, MDBK, CV-1, Hela, HepG2, P19, F9, CHO, PC12, 293 cell, BAF3, Jerkat, human PBMC, MT-4, Molt-4, NIH3T3, L929, chicken embryo fibroblast, etc.

[0025] The present inventors have shown that Sendai virus cDNA reconstitutes particles more efficiently when cDNA to be introduced into cells is in a linear form than in a circular form, and that transcription of a (+)RNA in cells more successfully forms particles than that of a (-)RNA (A. Kato et al., Genes to Cells, 1: 569-579, 1996). Although these conditions may not always be applicable to the reconstitution of all other (-)RNA viruses, it is possible to determine the appropriate conditions for the reconstitution of other (-)RNA viruses according to the description of the present specification and based on conventional technology.

[0026] The produced complex can be recovered by the standard methods from the host, for example, cultured cells or embryonated chicken eggs.

[0027] A foreign gene encoded by the RNA constituting a complex can be expressed by infecting cells with the complex. Namely, the foreign gene can be expressed *in situ* by inoculating the complex or a cell carrying it into a host such as embryonated chicken eggs or appropriate tissues of an animal body. Alternatively, cells recovered from a living body are transformed so that the complex can autonomously replicate, and the transformed cells are returned to the living body to allow the cells to express the foreign gene.

[0028] As an embodiment of the present invention, Figure 9 shows the processes of infecting target cells with a Sendai virus complex in which the M gene is deleted or inactivated and infiltrating the RNA of the present invention into surrounding non-infected cells through contact infiltration.

09762644.072004

Brief Description of the Drawings

**[0029]** Figure 1 schematically shows the structure of the plasmid pUC18/T7(+ )HVJRz.

**[0030]** Figure 2 schematically shows the region carrying the M gene in Sendai virus cDNA and procedure for subcloning or mutating said region. In the figure, E stands for transcription termination sequence; I, intervening sequence; and S, transcription initiation sequence. Boxes indicate the restriction sites used for the plasmid construction.

**[0031]** Figure 3 schematically shows procedures for introducing mutation to the M gene region of Sendai virus cDNA. Upper panel of A shows the structure of Sendai virus genome with each position of the NP, P(P/C), M, F, HN, and L genes. Lower panel shows the structure of the M gene, restriction sites, and positions of primers M1 and M2 used for the construction of the M defect type. B and C schematically show the construction of the M defect type and the M deletion type, respectively. Crossed out restriction sites indicate that they are mutated to be indigestible by the enzymes. D shows comparison between the M defect and wild type M genes in terms of both nucleotide and amino acid sequences. Dots in the M defect sequences mean that bases or amino acids are identical to the corresponding wild type sequences. [Ter] indicates a termination codon. Numerals indicate the base/amino acid position in the M gene sequence.

**[0032]** Figure 4 schematically shows procedure for subcloning the M gene region of Sendai virus cDNA. Crossed out restriction sites indicate that they are mutated to be indigestible by the enzymes.

**[0033]** Figure 5 schematically shows the construction of the M deletion type cDNA by mutating the subcloned Sendai virus M gene region and replacing the full-length M gene region of Sendai virus cDNA with the mutated one. Crossed out restriction sites indicate that they are mutated to be indigestible by the enzymes.

**[0034]** Figure 6 schematically shows the construction of the M defect type cDNA by mutating the subcloned Sendai virus M gene region, and replacing the full-length M gene region of Sendai virus cDNA with the mutated one. Crossed out restriction sites indicate that they are mutated to be indigestible by the enzymes.

09762641.072001

[0035] Figure 7 shows plaques of Sendai virus cDNA of wild type (WT1 and WT2); M defect type (dM); and M deletion type (dMEA2-1 and dMEA2-2).

[0036] Figure 8 shows plaques of Sendai virus cDNA of wild type (WT); M defect type (dM); and M deletion type (dMEA), which were stained with anti-Sendai virus antibody.

[0037] Figure 9 illustrates the process of contact infiltration by Sendai virus genome of wild type genome (upper panel) and of the mutant with mutated or no M gene (lower panel). The wild type forms infective virus particles and causes contact infiltration, while the mutant is not able to form infective particles but introduces its genome into non-infected surrounding cells only by contact infiltration.

#### Best Mode for Carrying out the Invention

[0038] The present invention will be illustrated in detail below with reference to Examples, but is not to be construed as being limited thereto.

#### Example 1. Subcloning of the M gene of Sendai virus

[0039] All of the following ligation, blunting, and dephosphorylation were performed using the Takara Ligation Kit Ver.2 (Takara Shuzo, Kyoto, Japan), the Takara Blunting Kit (Takara Shuzo), and CIAP (Takara Shuzo), respectively, according to the manufacture's protocols attached to the products. The nucleotide sequences were determined by Sanger's method (F. Sanger, Science, 214: 1205-1210, 1981).

[0040] Complementary DNA in which the M gene was deleted was constructed as follows, using wild type cDNA, pUC18/T7(+)-HVJRz (A. Kato et al., Genes to Cells, 1: 569-579, 1996) (Figure 1). The DNA sequences of the M gene and its vicinity are shown in Figure 2, and the construction scheme is shown in Figure 3.

[0041] First, the ClaI fragment containing the M gene was excised from pUC18/T7(+)-HVJRz and inserted into the ClaI site of pHSG396 (Takara Shuzo) to obtain pHSG-M-CC (Figure 4). Separately, pHSG396 was digested with ApaLI, blunted, and self-ligated to obtain pHSG396-dA that lacks the ApaLI site (Figure 4). The EcoRI-BamHI fragment of pHSG-M-CC carrying the M gene was inserted into dephosphorylated EcoRI-BamHI-digested pHSG396-dA to obtain pHSG-dA-M-BE (Figure 4).

09762644-03901

Example 2. Construction of M deletion type vector

[0042] Forty nine-mer synthetic oligonucleotides, 5'-ggcgatatctatagattccctaagttctcatagtagatgtgcaccggca-3' (EA linker F) (SEQ ID NO: 1) and 5'-tgccggtgcacatctactatgagaacttagggaatctatagatcgcc-3' (EA linker R)(SEQ ID NO: 2), were annealed and inserted into pCR2.1 (Invitrogen) to generate pCR-EAL. The nucleotide sequence of the insert was verified to be as designed.

[0043] The pCR-EAL was digested with EcoRV and ApaLI, and the linker fragment was excised. Separately, the pHSG-dA-M-BE was digested with EcoRV and ApaLI and the above linker fragment was inserted therein to obtain pHSG-dA-dM-EA-EB.

[0044] The pHSG396 was digested with EcoRI, blunted, and self-ligated to obtain a plasmid lacking the EcoRI site, which was further digested with BamHI, blunted, and self-ligated to obtain pHSG-dE-dB, a plasmid lacking both EcoRI and BamHI sites.

[0045] The ClaI fragment carrying the M gene was inserted into the ClaI site of pHSG-dE-dB to generate pHSG-dE-dB-M-CC. The EcoRI-BamHI fragment excised from pHSG-dA-dM-EA-EB was inserted into the EcoRI-BamHI-digested pHSG-dE-dB-M-CC to obtain pHSG-dE-dB-dM-CC.

[0046] The ClaI fragment of pHSG-dE-dB-dM-CC was inserted into the ClaI site of the pUC18/T7(+)-HVJRz to obtain pHVJ-dMEA. This construction scheme is shown in Figure 5.

Example 3. Construction of M defect type vector

[0047] PCR was performed using pUC18/T7(+)-HVJRz as a template with oligonucleotide primers, M-1 (5'-ttaaaggcctaaccgatctcagaattacg-3')(SEQ ID NO: 3), and M-2 (5'-tatcattccctgtctcagcctgcc-3')(SEQ ID NO: 4). The primers were designed to introduce a mutation at the BsgI site of the M gene so that a stop codon appears in frame of the M gene. The PCR products were subcloned into pCR2.1 to obtain pCR-M (Figure 6).

[0048] Following verification of the nucleotide sequence of pCR-M, the StuI-XcmI fragment of pCR-M was recovered from the gel and inserted into the StuI-XcmI-cut pHSG-M-CC. The resulting plasmid was named as pHSG-dM-CC. The ClaI fragment of pHSG-dM-CC was inserted into the ClaI site of pUC18/T7(+)-HVJRz to obtain pHVJ-dM. This construction scheme is shown in Figure 6.

09762641.02001  
1002749260



Example 4. Reconstitution of virions from M deletion type and M defect type cDNAs

[0049] Reconstitution of virions from cDNA of wild type (WT), M deletion type (dMEA), and M defect type (dM) was performed as follows.

[0050] Cultured LLCMK2 cells (a simian kidney cell line) were detached from a dish by treatment with trypsin, and  $2 \times 10^6$  cells were plated in a plastic dish of 10 cm diameter and incubated in MEM medium (Gibco BRL) supplemented with 10% FBS (Gibco BRL) at 37°C for 24 hours in 5% CO<sub>2</sub>. The medium was then removed, and the cells were washed once with PBS. Five hundred µl of a solution of vTF7-3, a recombinant vaccinia virus vector capable of expressing T7 phage RNA polymerase (T.R. Fuerst et al., Proc. Natl. Acad. Sci. USA, 83:8122-8126, 1986), which was diluted with PBS to  $8 \times 10^6$  pfu/ml to obtain MOI (multiplicity of infection) of 2, was added dropwise to the dish. The cells were infected for 1 hour with agitating the dish every 15 minutes to spread the virus solution over the whole dish.

[0051] Separately, a medium containing a cDNA solution was prepared as follows. First, 500 µl Opti-MEM (Gibco BRL) without FCS (fetal calf serum) was added into a polystyrene tube, and then any of pUC18/T7(+)HVJRz, pHVJ-dMEA or pHVJ-dM, all plasmids originating from Sendai virus cDNA (20 µg), pGEM-NP (5 µg), pGEM-P (2.5 µg), and pGEM-L (5 µg) were added. Fifty µl SuperFect (QIAGEN) was further added, and the mixture was allowed to stand at room temperature for 20 minutes. Ten ml of Opti-MEM was then added. Subsequently, Rifampicin and Cytosine arabinoside (Ara C) were added at the final concentration of 100 µg/ml and 40 µg/ml, respectively.

[0052] After 1-hour infection, the virus solution was removed from the above dish containing LLCMK2 cells, the medium containing the above cDNA solution was added to the culture by decantation, and the cells were incubated at 37°C for 48 hours in 5% CO<sub>2</sub>. The cells were scraped using a cell scraper without removing the medium, and the cells and the medium were transferred together to a 15-ml centrifuge tube. After centrifugation at 1200 rpm for 5 minutes, the supernatant was removed, and the precipitated cell was resuspended in 200 µl of PBS.

Example 5. Inoculation of cell suspensions to embryonated chicken eggs and HA assay

[0053] To evaluate virus reconstitution, an assay using embryonated chicken eggs was performed. The cells suspended in 200 µl of PBS obtained in Example 4 were adjusted to  $1 \times$

09762541.072001

$10^7$  cells/ml and sequentially diluted with PBS to obtain cell suspensions of  $1 \times 10^6$  and  $1 \times 10^5$  cells/ml. One hundred  $\mu$ l of each suspension was inoculated to a 10-day-old embryonated chicken egg through the air chamber side using a 24G needle.

**[0054]** The chicken eggs were incubated at  $35.5^\circ\text{C}$  for 3 days with rotating. Then, the eggshell at the air chamber was cut out, and urine was collected using a 10-ml syringe with 18G needle.

**[0055]** The collected urine was tested by HA assay to evaluate virus propagation in the chicken eggs. HA assay was performed as follows.

**[0056]** Fifty  $\mu$ l of PBS was dispensed into each well of from the second to the 12th lines of a 96-well round bottom plate. One hundred  $\mu$ l of the urine sample was added to the first line. Fifty  $\mu$ l of the sample in the first line was mixed with PBS in the second line to make a 1:2 dilution. Fifty  $\mu$ l of the 1:2 dilution was mixed with PBS in the third line to make a 1:4 dilution. By repeating the procedure, a series of two-fold dilutions were made.

**[0057]** Fifty  $\mu$ l of 1% chicken preserved blood (Cosmo Bio) diluted with PBS was added to all the lines, and the plate was kept at  $4^\circ\text{C}$  for 1 hour. Erythrocyte aggregation was examined with the naked eye and the highest dilution that results in the aggregation was shown as HA activity (Table 1).

Table 1

Virus cDNA	HA activity
WT (wild type)	> 16
dM (defect)	< 2
dMEA2-1 (deletion)	< 2
dMEA2-2 (deletion)	< 2

**[0058]** Virus cDNAs used were of viruses, wild type (pUC18/T7(+)-HVJRz; WT), the M defect type (pHVJ-dM; dM), and the M deletion type (pHVJ-dMEA; dMEA). For the M deletion type, the results of two experiments were shown (dMEA2-1, and dMEA2-2). The wild type virus showed an activity higher than 16, whereas the other samples did not show any significant activity. The result indicates that the Sendai virus cDNA in which the M gene

09762641.072001

is deleted or is defective did not produce a virus with disseminative capability in the standard reconstitution experiment.

Example 6. Plaque formation

[0059] CV-1 cells were plated at  $5 \times 10^5$  cells/well into a 6-well plate (Corning, microplate 6-well) and cultured overnight.

[0060] LLCMK2 cells obtained in Example 4 were diluted with PBS to  $1 \times 10^6$  cells/ml, and 100  $\mu$ l of the suspension was dispensed into 1.5 ml microtubes (Eppendorf). A portion of the dispensed suspensions was subjected to three repeats of freeze-thawing by freezing at  $-80^\circ\text{C}$  for 10 minutes and thawing in water at room temperature for 3 minutes. Trypsin was added to all the cell suspensions at the final concentration of 0.75  $\mu\text{g/ml}$  and the mixtures were incubated at  $37^\circ\text{C}$  for 30 minutes.

[0061] The media were removed from the plates of CV-1 cell culture, and the cells were washed once with PBS, then overlaid with 100  $\mu$ l of the above diluted cell suspension treated with trypsin. The mixtures were incubated for 1 hour with agitating every 15 minutes so as to spread the suspension over the whole plate. The plates were overlaid with 3 ml of 1 x MEM containing 1% agar, supplemented with 0.1% BSA, Rifampicin 100  $\mu\text{g/ml}$ , Ara C 40  $\mu\text{g/ml}$ , and trypsin 0.75  $\mu\text{g/ml}$ , that was preheated to approximately  $45^\circ\text{C}$ . After the agar solidified, the plates were inverted and incubated at  $37^\circ\text{C}$  for 5 days in 5%  $\text{CO}_2$ .

[0062] Then, 1 ml of a fixative (ethanol:acetic acid = 5:1) was added onto the agar, and the plates were allowed to stand at room temperature for 90 minutes. The agar was then removed, and 200  $\mu$ l of Amido Black solution (0.5% Amido Black, ethanol:acetic acid:water = 45:10:45) was added. Immediately thereafter, the cells were washed with water and stained to count the plaque number and evaluate the shapes of plaques. The results were shown in Table 2 and Figure 7.

Table 2

Reconstitution efficiency of Sendai virus deficient or defective in the M gene

M gene	Number of plaques		
	freeze-thawed		not frozen
	Run 1	Run 2	
wild type	38	22	14
M defect type (dM)	2	4	2
M deletion type (dMEA2-1)	27	26	60
M deletion type (dMEA2-2)	32	38	42

**[0063]** Virus cDNAs used are of wild type (pUC18/T7(+)-HVJRz), the M defect type (pHVJ-dM), and the M deletion type (pHVJ-dMEA). For the M deletion type, the results of two experiments (dMEA2-1 and dMEA2-2) are shown. The number of plaques was counted for both freeze-thawed and not frozen cell suspensions. The plaque number reflects the number of reconstituted viruses in  $1 \times 10^5$  transfected LLCMK2 cells. Experiments using freeze-thawed samples were performed twice (runs 1 and 2). Although it was reported that reconstitution efficiency of Sendai virus decreases in a mutant virus such as an addition type in which a foreign gene was inserted into genome (Hasan et al., J. Gen. Virol. 78: 2813-2820, 1997), the M deletion type showed a comparable reconstitution efficiency to that of wild type. The M defect type showed a little lower efficiency. Freeze-thawing of the transfected cells did not significantly affect the plaque number.

**[0064]** As is evident from Table 2 and Figure 7, plaques that are supposed to be derived from cDNAs of the M deletion type and the M defect type were observed. The size of the plaques was much smaller than that of wild type formed in simultaneous positive control (Figure 7; WT1 and WT2). To further examine the shape of the plaques, they were stained with anti-Sendai virus polyclonal antibody, which was produced by the known method by inoculating rabbits with purified Sendai virus that was inactivated as antigens.

**[0065]** The plaques described in Example 6, which were fixed and stained with Amido Black, were hybridized with anti-Sendai virus antibody, and subsequently with FITC-conjugated anti-rabbit IgG or with anti-mouse IgG antibody, then observed under fluorescence stereoscopic microscope. As a result, signal was detected in plaques of wild

09763641-02001

type, the M deletion type, and the M defect type, confirming that the plaques were of Sendai viruses (Figure 8).

[0066] It was observed that the plaques of wild type cDNA were almost circular, whereas those of the M deletion type and the M defect type cDNAs were small and not circular, having irregular shapes (Figure 8).

Example 7. Antibody staining of plaques

[0067] To determine whether the plaques, different from those of wild type in size and shapes, are derived from cDNA of the M deletion type or the M defect type, the presence of M protein was examined. Namely, these plaques were stained with anti-M protein monoclonal antibody and observed under fluorescence stereoscopic microscope.

[0068] Immunofluorescence staining of the plaques was performed as follows. Plaques were stained with Amido Black. The position of the plaques was examined with the naked eye and marked with a marker pen. Each well of 6-well plates that contains plaques was washed once with 1 ml of PBS, overlaid with 200  $\mu$ l of 1:40 diluted anti-M protein monoclonal antibody, and incubated at 37°C for 45 minutes in a CO<sub>2</sub> incubator. Then, the well was washed three times with 1 ml of PBS, overlaid with 200  $\mu$ l of 1:100 diluted FITC-conjugated anti-mouse IgG antibody (Cosmo Bio), and incubated at 37°C for 45 minutes in an incubator. Finally, each well was washed three times with 1 ml of PBS, overlaid with 1 ml of PBS. The staining of the marked plaques was then examined under fluorescence stereoscopic microscope.

[0069] Thereafter, the same procedure was repeated processed using anti-Sendai virus polyclonal antibody as the first antibody and FITC-conjugated anti-rabbit IgG antibody (ICN Biomedicals) as the second antibody. The wells were then observed under fluorescence stereoscopic microscope again.

[0070] The plaques from wild type cDNA were stained with both anti-Sendai virus antibody and anti-M protein monoclonal antibody. In contrast, plaques from cDNA of the M deletion or defect type were stained with anti-Sendai virus antibody, but not with anti-M protein monoclonal antibody. This indicates that the latter plaques, lacking complete M protein, are derived from cDNA of the M deletion and defect types.

09762641.072001

[0071] Accordingly, plaques from Sendai virus gene having a deletion or defect in the M gene were obtained. Since the virus forming plaques does not propagate in chicken eggs, the virus is supposed to be incapable of budding, i.e. not disseminative. In addition, the virus is supposed to be capable of contact infiltration as it forms plaques.

[0072] This mode of propagation is probably due to cell fusion mediated by F and HN proteins. Namely, among proteins encoded by Sendai virus, F and HN proteins are expressed as a membrane protein on the cell surface, and M protein supports F and HN proteins as an intracellular anchor in virus budding. In case of the M deletion type and M defect type, budding does not occur because the anchor is lost. However, F and HN proteins are expressed on the cell surface, and cell fusion occurs mediated by these proteins, so that virus genome can be transferred into surrounding cells. In this way, it is possible to realize virus propagation without budding (Figure 9).

#### Industrial Applicability

[0073] The present invention enables providing an RNA virus vector capable of cell infection, autonomous RNA replication, and infiltration through contact, but incapable of dissemination. By utilizing the RNA virus vector of the present invention, it is possible to carry out more efficient gene introduction and cell transplantation in gene therapy.

09762641.072001

## CLAIMS

1. An RNA molecule that forms a complex capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination, wherein said RNA comprises genes involved in contact infiltration and autonomous RNA replication, but no or inactivated genes involved in dissemination.

2. The RNA molecule according to claim 1, wherein genes encoding a protein that interacts with the envelope and the virus core is deleted or inactivated.

3. The RNA molecule according to claim 2, wherein said protein that interacts with the envelope and the virus core is Matrix protein (M protein).

4. The RNA molecule according to claim 1, wherein said RNA molecule is derived from a non-segmented (-)RNA virus.

5. The RNA molecule according to claim 1, wherein said RNA molecule is derived from Sendai virus and comprises no or inactivated gene encoding M protein.

6. The RNA molecule according to any one of claims 1 to 5, wherein said RNA molecule comprises a foreign gene.

7. A cell comprising the RNA according to any one of claims 1 to 6, wherein the cell is capable of allowing said RNA to replicate and transmitting said RNA to another cell through contact infiltration.

8. A DNA molecule comprising a template DNA for transcribing the RNA according to any one of claims 1 to 6 *in vitro* or in cells.

9. A complex capable of cell infection, autonomous RNA replication, and contact infiltration, but incapable of dissemination, wherein said complex comprises the RNA molecule of any one of claims 1 to 6 and a virus structure without nucleic acid.

09762641.072004  
FOIA b7 - D

10. A kit comprising a) the RNA according to any of claims 1 to 6, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and b) a group of enzymes required for replication of said RNA or said cRNA, or a unit that is capable of biosynthesizing said enzymes.

11. The kit according to claim 10, wherein a) is the RNA according to claim 5 or 6, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and b) is all of the proteins, NP, P/C, and L of Sendai virus, or a unit that is capable of biosynthesizing said proteins.

12. A method for producing the complex according to claim 9, wherein said method comprises introducing into a host a) the RNA of any one of claims 1 to 6, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and b) a group of enzymes required for replication of said RNA or said cRNA, or a unit that is capable of biosynthesizing said enzymes.

13. The method according to claim 12, wherein a) is the RNA of claim 5 or 6, a cRNA of said RNA, or a unit that is capable of biosynthesizing said RNA or said cRNA, and b) is all of the proteins, NP, P/C, and L of Sendai virus, or a unit that is capable of biosynthesizing said proteins.

14. A method for expressing a foreign gene, wherein said method comprises inoculating the cell of claim 7 into a nonhuman mammal and allowing a cell contacted with said cell to express a foreign gene.

09762644.072001



## ABSTRACT

The present invention provides an RNA virus vector useful for gene therapy. The RNA virus vector is capable of cell infection, autonomous RNA replication, and infiltration through contact, but incapable of dessimination. The use of the RNA virus vector of the present invention enables more efficient gene transfer and cell transplantation in gene therapy compared with the conventional techniques.

Gray Cary\GT\6224097.1  
9999998-91028

09762641.072001

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY** (Includes Reference to PCT International Applications)ATTORNEY'S DOCKET NO.  
SHIM1100

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**RNA VIRUS VECTOR WITH CONTACT INFILTRATION CAPABILITY**

the specification of which (check only one item below):

☐ is attached hereto.

☒ was filed as United States application  
Serial No. 09/762,641  
on February 8, 2001  
and was amended  
on \_\_\_\_\_ (if applicable).

☐ was filed as PCT international application  
Number \_\_\_\_\_  
on \_\_\_\_\_  
and was amended under PCT Article 19  
on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim foreign priority benefit under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY (If PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Japan	10/227398	11 August 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
PCT	PCT/JP99/04333	10 August 1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

<b>COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED)</b> (Includes Reference to PCT International Applications)				ATTORNEY'S DOCKET NO. SHIM1100	
I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS				STATUS (MARK ONE)	
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)			
POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration no.)					
CUSTOMER NUMBER		28,213		PLACE CUSTOMER LABEL HERE	
SEND CORRESPONDENCE TO		LISA A. HAILE, REG. NO. 38,347 GRAY CARY WARE & FREDENRICH 465 Executive Drive, Suite 1000 San Diego, CA 92121-2139		DIRECT TELEPHONE CALLS TO LISA A. HAILE Telephone: 858-677-1456 Fax: 858-677-1465	
201	FULL NAME OF INVENTOR	FAMILY NAME <u>ASAKAWA</u>	FIRST GIVEN NAME <u>Makoto</u>	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>Toyonaka-shi</u>	STATE OR FOREIGN COUNTRY <u>Osaka</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 319 Shionogi-Kanzakigawa-Ryo, 2-1, Futaba-cho 3-chome		CITY <u>Toyonaka-shi</u> STATE & ZIP CODE/COUNTRY <u>Osaka 561-0825 Japan</u> <i>JAX</i>	
202	FULL NAME OF INVENTOR	FAMILY NAME <u>HASEGAWA</u>	FIRST GIVEN NAME <u>Mamoru</u>	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>Tsukuba-shi</u>	STATE OR FOREIGN COUNTRY <u>Ibaraki</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS c/o Dनावेक Research Inc., 25-11, Kamondai 1-chome		CITY <u>Tsukuba-shi</u> STATE & ZIP CODE/COUNTRY <u>Ibaraki 305-0856 Japan</u> <i>JAX</i>	
203	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
ADDITIONAL INVENTOR INFORMATION ATTACHED I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any issuing thereon.					
SIGNATURE OF INVENTOR 201 <i>Makoto Asakawa</i>		SIGNATURE OF INVENTOR 202 <i>Mamoru Hasegawa</i>		SIGNATURE OF INVENTOR 203	
DATE: <i>June 21, 2001</i>		DATE: <i>July 3, 2001</i>		DATE:	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Asakawa et al                      Art Unit:              Unknown  
Serial No.: 09/762,641                      Examiner              Unknown  
Filed: February 8, 2001  
Title: RNA VIRUS VECTOR WITH CONTACT INFILTRATION CAPABILITY

Assistant Commissioner for Patents  
Washington, DC 20231

**POWER OF ATTORNEY BY ASSIGNEE**

As a below-named assignee of the above-identified application ("Application"):

I hereby appoint the following attorneys of the assignee to prosecute the Application and to transact all business in the United States Patent and Trademark Office connected therewith:

Customer Number	28,213
-----------------	--------


I hereby authorize and request insertion of the application number of the Application when officially known.

Please direct all telephone calls to LISA A. HAILE, Ph.D. at (858) 677-1456 and address all correspondence to LISA A. HAILE, Ph.D., GRAY CARY WARE & FREIDENRICH, 4365 Executive Drive, Suite 1600, San Diego, California 92121.

**DNAVEC RESEARCH INC.**

A Japanese Corporation

By: \_\_\_\_\_



Name: \_\_\_\_\_

Hirotaka Nakatomi

Title: \_\_\_\_\_

President

Date: \_\_\_\_\_



09/762,641-022001